

REMARKS

The Notice indicated that the use of <220> to <223> is mandatory if the designation of "Artificial Sequence" is used for the identifier <213>. See Notice on page 3 in ¶ 11 of the "Raw Sequence Listing Error Summary". The Notice then requested an explanation of the source of the genetic material in the sections <220> to <223>. See id.

Applicants respectfully traverse the objection because the Sequence Listing already on file clearly indicates in the sections <220> to <223> that the sequences are "peptide constructs". The designation of "peptide constructs" adequately shows that the peptide are synthesized, and thus shows that the source of the genetic material is from an artificial source given that all "peptide constructs" must be artificially created.

However, in order to expedite prosecution of the application, Applicants have changed the designation in <223> from "peptide constructs" to "completely synthesized peptide construct". The designation of "completely synthesized peptide construct" should set forth in no uncertain terms that the peptide is from an artificial source.

The Notice further stated that the <221> MISC_FEATURE

designation of cyclohexylalanine, D-alanine, acetyl, ClAc or BrAc in the position (1) for many of the sequences is incorrect because Asn (N) or some other amino acid is present in the position (1). See Notice at page 1 to 8 of the "Raw Sequence Listing". The handwritten notes also object to the presence of cyclohexylalanine or D-alanine in the <221> MISC_FEATURE designation. The notes further suggest changing the first position of the sequence into the variable "Xaa" with further explanation in <220> to <223>.

Applicants again traverse the objections. However, in order to expedite prosecution, Applicants have amended the relevant sequences to change the <221> MISC_FEATURE at the position (1) to recite "acetyl, ClAc or BrAc" and deleted "cyclohexylalanine" or "D-alanine" from the definition.

The first position for each of the relevant sequences has also been changed into the variable "Xaa" wherein the definition in <220> to <223> indicates the types of possible amino acids. The definition in <220> to <223> further provides that when X is Ala (A), then Ala (A) is either cyclohexylalanine or D-alanine, hence covering the deleted "cyclohexylalanine" or "D-alanine" from the previous definition.

Accordingly, Applicants respectfully submit that the amended Sequence Listing overcomes the objections indicated in the hand-

written notes. Applicants enclose a Summary Report from the Checker 4.4.0 program showing that no errors are present for the enclosed Sequence Listing.

Applicants also submit substitute sheets of the "Sequence Listing". Two compact discs that are the computer readable form required under § 1.821(e) including all previously submitted data with the amendment to the "Sequence Listing" incorporated therein are enclosed. No new matter is added by the computer readable form of the sequences or by the amended paper copy of the Sequence Listing.


Applicants also at this time submit an Information Disclosure Statement (IDS) citing the references cited in the corresponding European application.

CONCLUSION

In view of the remarks and submissions, Applicants respectfully submit that all the requested items have been submitted and that all the requirements under 37 C.F.R. 1.821-1.825 have been satisfied. A copy of the Notice is enclosed herewith.

Respectfully submitted,

SHERMAN AND ASSOCIATES



Attorney for Applicants
Roger C. Hahn
Reg. No. 46,376

SHERMAN AND ASSOCIATES
415 N. Alfred Street
Alexandria, Virginia 22314
703-549-2282